title: [Determination of the carcinoembryonic antigen (CEA) for predicting the success of therapy in metastatic breast cancer].
abstract: In 53 patients with metastatic breast cancer and increased CEA serum levels (greater than 10 micrograms/l) the CEA titer within the first 8 weeks after commencement of chemotherapy was compared with results of therapy. Among 30 patients in whom CEA values had decreased by at least 30% of pretreatment values 12 showed remission, 15 no change and 3 progression of the malignancy. Among 23 patients with unchanged or increasing CEA values during therapy 19 had progression, 3 an arrest and one a remission of the disease. In the one patient with remission the course of the disease was unusual inasmuch as the CEA value increased to 240 micrograms/l serum and liver metastases regressed excessively at the same time. This lead to the assumption of CEA release by tumour necrosis during therapy. The results suggest that in metastatic breast cancer and increased CEA values remission generally cannot be expected should the CEA value remain unchanged or rise within the first 8 weeks after initiation of treatment. In contrast, a decrease of CEA within that time may be considered a prognostically favourable sign which, however, does not mean clinically relevant reduction of tumour size in every case. For evaluation of treatment sufficient precision of CEA determinations must be guaranteed.
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D004359:Drug Therapy, Combination; D005260:Female; D006728:Hormones / Q000008:administration & dosage; D006801:Humans; D009362:Neoplasm Metastasis; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D006728:Hormones
vernacular_title: Bestimmung des carcinoembryonalen Antigens (CEA) zur Voraussage des Therapieerfolges beim metastasierenden Mammakarzinom.